The Canadian Rett Syndrome Coalition - comprising the Rett Syndrome Society of British Columbia (RSSBC), Rett Syndrome Society of Alberta (RSSA), Saskatchewan Rett Syndrome Association (SRSA), ...

Three-year-old Meher from Noida was diagnosed with Turner Syndrome at PGICH using QF-PCR, a first for the institute. Early ...

So these studies include the [emugrobart] data in SMA and FSDH and the CT-868 data in type 1 diabetes and the CT-996 data ... spikes in diabetic sugar measurements as well as exacerbations of ...

Unresolved compliance issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's lead drug for spinal muscular atrophy (SMA). The CRL is related ...

Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will now need to revise its application if it hopes to secure an FDA nod. The ...

A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.

SonicWall has released a firmware update that can help customers remove rootkit malware deployed in attacks targeting SMA 100 series devices. "SonicWall SMA 100 10.2.2.2-92sv build has been released ...

Eldest daughter syndrome isn't in the DSM-5, but that doesn't make the experiences of eldest daughters any less real. Eldest daughter syndrome can look like intense perfectionism, unrealistic high ...

BETHESDA, Md. — Exactly one year ago, in these pages, I implored Congress to receive classified testimony from me about State Department and CIA efforts to cover up evidence and intelligence of the so ...

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Being the eldest daughter isn’t always easy—so much so that it’s the topic ...

2025年10月，专注于RNA靶向药物研发的Ionis ...

Scholar Rock’s bid to become the first company to win FDA approval for a muscle-targeted treatment for spinal muscular atrophy (SMA) has been tripped up by a manufacturing issue. The FDA sent a ...